|Have Questions?||Leave a Message or Start an on-line Chat|
The CD63 recombinant monoclonal antibody is produced using DNA recombinant technology and in vitro genetic manipulation. The process begins with immunizing an animal with a synthesized peptide derived from human CD63. B cells are isolated and screened to select positive cells. Single clone identification is performed to ensure the purity of the antibody. The genes encoding the light and heavy chains of the CD63 antibody are amplified through PCR and inserted into a plasmid vector to create a recombinant vector. This vector is then transfected into a host cell line for antibody expression. The CD63 recombinant monoclonal antibody is purified from the cell culture supernatant using affinity chromatography. It is specifically designed to bind to human CD63 protein and can be used in ELISA, IHC, and IF applications.
CD63 is involved in multiple cellular processes, including cell adhesion, migration, signaling, and vesicular trafficking. It is also known to be involved in exosome biogenesis, where it helps to sort and package proteins and lipids into intraluminal vesicles for release into the extracellular space. CD63 is a marker of exosomes and is often used as a reference marker for the isolation and characterization of these extracellular vesicles. CD63 also participates in antigen presentation, as it plays a role in the transport of MHC class II molecules to the cell surface.
There are currently no reviews for this product.